Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

2.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
3.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
4.

Effect of aripiprazole on verbal memory and fluency in schizophrenic patients : results from the ESCAPE study.

Bervoets C, Morrens M, Vansteelandt K, Kok F, de Patoul A, Halkin V, Pitsi D, Constant E, Peuskens J, Sabbe B.

CNS Drugs. 2012 Nov;26(11):975-82. doi: 10.1007/s40263-012-0003-4. Erratum in: CNS Drugs. 2012 Nov;26(11):1011-2.

PMID:
23018547
5.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
6.

Aripiprazole versus other atypical antipsychotics for schizophrenia.

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J.

Cochrane Database Syst Rev. 2014 Jan 2;(1):CD006569. doi: 10.1002/14651858.CD006569.pub5. Review.

PMID:
24385408
7.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

8.

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.

Adams DH, Kinon BJ, Baygani S, Millen BA, Velona I, Kollack-Walker S, Walling DP.

BMC Psychiatry. 2013 May 22;13:143. doi: 10.1186/1471-244X-13-143.

9.

Aripiprazole versus other atypical antipsychotics for schizophrenia.

Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh HG, Leucht S.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD006569. doi: 10.1002/14651858.CD006569.pub4. Review. Update in: Cochrane Database Syst Rev. 2014;(1):CD006569.

PMID:
23450570
10.

Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.

Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M.

Psychopharmacol Bull. 2010;43(2):45-66. Review.

PMID:
21052042
12.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
13.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

14.

Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.

Rosa F, Schreiner A, Thomas P, Sherif T.

Clin Drug Investig. 2012 Apr 1;32(4):267-79. doi: 10.2165/11599080-000000000-00000.

PMID:
22339430
15.

Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.

Kishi T, Moriwaki M, Kitajima T, Kawashima K, Okochi T, Fukuo Y, Furukawa O, Naitoh H, Fujita K, Iwata N.

Psychopharmacology (Berl). 2010 Apr;209(2):185-90. doi: 10.1007/s00213-010-1787-x. Epub 2010 Feb 23.

PMID:
20177883
16.

Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.

Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S.

Schizophr Bull. 2012 Jun;38(4):845-53. doi: 10.1093/schbul/sbq172. Epub 2011 Feb 9.

17.

The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.

Parabiaghi A, D'Avanzo B, Tettamanti M, Barbato A; GiSAS Study Group.

Contemp Clin Trials. 2011 Sep;32(5):675-84. doi: 10.1016/j.cct.2011.04.008. Epub 2011 Apr 30.

PMID:
21554991
18.

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, Howe A.

J Clin Psychiatry. 2011 Apr;72(4):502-8. doi: 10.4088/JCP.10m06618.

PMID:
21527125
19.

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.

Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.

Schizophr Res. 2008 Jan;98(1-3):8-15. Epub 2007 Jun 26.

PMID:
17596914
20.

The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.

Naber D, Lambert M.

CNS Drugs. 2009 Aug;23(8):649-59. doi: 10.2165/00023210-200923080-00002.

PMID:
19594194

Supplemental Content

Support Center